Continuation of Bevacizumab After Progression May Not Improve Survival Outcomes in NSCLC
AvaALL was the first phase 3 study to evaluate bevacizumab across multiple lines of treatment beyond progression in patients with non-small cell lung cancer.
All articles by James Nam, PharmD
Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL
The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.
Capmatinib Plus Gefitinib May Be Effective in Some Forms of Resistant Non-Small Cell Lung Cancer
Capmatinib has demonstrated preclinical activity in EGFR-mutant and MET-activated non-small cell lung cancer when administered with concurrent EGFR-TKIs.
Cancer-Related Fatigue May Predict Reduced Survival in Newly Diagnosed Multiple Myeloma
Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.
Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials
The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.
Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence
Radiotherapy after surgery may modify ipsilateral breast tumor recurrence risk among different subtypes of breast cancer.
Evaluation of Available Frontline Induction Therapies for Multiple Myeloma
There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.
S-1 Monotherapy May Be as Effective as Platinum-Based Regimens in Non-Small Cell Lung Cancer
Evidence suggests that S-1 monotherapy may be safe and effective in non-small cell lung cancer.
Ibrutinib Plus Rituximab Granted FDA Approval for Waldenström Macroglobulinemia
Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.
Half-Dose R-CHOP May Be Effective, Reduce Toxicity, in Waldenström Macroglobulinemia
Due to its rarity, there is neither robust evidence nor many completed studies supporting specific treatment regimens in Waldenström macroglobulinemia.
Next post in Hematologic Cancers
